文献速递白血病造血干细胞移植与细胞治疗

4岁以下急性淋巴细胞白血病患者接受化疗预处理方案行造血干细胞移植的非复发死亡率低:一项3期FORUM研究

Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.
PubMed 文献 · Blood Adv · 2024-01-01

FORUM研究(NCT01949129)评估了两种不含全身照射的预处理方案(氟达拉滨/塞替派/白消安 vs 氟达拉滨/塞替派/曲奥舒凡)在4岁以下急性淋巴细胞白血病患儿中的安全性、无事件生存期和总生存期。2013至2021年共191例患儿接受移植并随访至少6个月(中位随访3年)。两种方案耐受性良好且非复发死亡率低,但复发是治疗失败的主要原因。

要点

  • 3年总生存率:氟达拉滨/塞替派/白消安组0.63,氟达拉滨/塞替派/曲奥舒凡组0.76(P=0.075)。
  • 3年无事件生存率两组分别为0.52和0.51(P=0.794)。
  • 3年非复发死亡率低(0.06 vs 0.03),但复发累积发生率较高(0.42 vs 0.45)。

核心结论

  • 两种化疗预处理方案均耐受性良好且非复发死亡率低。
  • 复发是治疗失败的主要原因。

研究设计与样本

  • 3期FORUM研究(NCT01949129),评估两种不含全身照射的预处理方案在4岁以下急性淋巴细胞白血病患儿中的安全性、无事件生存期和总生存期。
  • 2013年至2021年共191例患儿接受移植并观察至少6个月,中位随访3年。
  • 患者接受氟达拉滨、塞替派联合白消安或曲奥舒凡预处理后行异基因造血干细胞移植。

主要发现

  • 3年总生存率:氟达拉滨/塞替派/白消安组0.63(95%CI 0.52-0.72) vs 氟达拉滨/塞替派/曲奥舒凡组0.76(95%CI 0.64-0.84)(P=0.075)。
  • 3年无事件生存率:氟达拉滨/塞替派/白消安组0.52(95%CI 0.41-0.61) vs 氟达拉滨/塞替派/曲奥舒凡组0.51(95%CI 0.39-0.62)(P=0.794)。
  • 3年非复发死亡率累积发生率:氟达拉滨/塞替派/白消安组0.06(95%CI 0.02-0.12) vs 氟达拉滨/塞替派/曲奥舒凡组0.03(95%CI <0.01-0.09)(P=0.406)。
  • 3年复发累积发生率:氟达拉滨/塞替派/白消安组0.42(95%CI 0.31-0.52) vs 氟达拉滨/塞替派/曲奥舒凡组0.45(95%CI 0.34-0.56)(P=0.920)。
  • >1级急性移植物抗宿主病发生率:氟达拉滨/塞替派/白消安组29% vs 氟达拉滨/塞替派/曲奥舒凡组17%(P=0.049);3/4级发生率分别为10%和9%(P=0.813)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) is highly effective for treating pediatric high-risk or relapsed acute lymphoblastic leukemia (ALL). For young children, total body irradiation (TBI) is associated with severe late sequelae. In the FORUM study (NCT01949129), we assessed safety, event-free survival (EFS), and overall survival (OS) of 2 TBI-free conditioning regimens in children aged <4 years with ALL. Patients received fludarabine (Flu), thiotepa (Thio), and either busulfan (Bu) or treosulfan (Treo) before HSCT. From 2013 to 2021, 191 children received transplantation and were observed for ≥6 months (median follow-up: 3 years). The 3-year OS was 0.63 (95% confidence interval [95% CI], 0.52-0.72) and 0.76 (95% CI, 0.64-0.84) for Flu/Thio/Bu and Flu/Thio/Treo (P = .075), respectively. Three-year EFS was 0.52 (95% CI, 0.41-0.61) and 0.51 (95% CI, 0.39-0.62), respectively (P = .794). Cumulative incidence of nonrelapse mortality (NRM) and relapse at 3 years were 0.06 (95% CI, 0.02-0.12) vs 0.03 (95% CI: <0.01-0.09) (P = .406) and 0.42 (95% CI, 0.31-0.52) vs 0.45 (95% CI, 0.34-0.56) (P = .920), respectively. Grade >1 acute graft-versus-host disease (GVHD) occurred in 29% of patients receiving Flu/Thio/Bu and 17% of those receiving Flu/Thio/Treo (P = .049), whereas grade 3/4 occurred in 10% and 9%, respectively (P = .813). The 3-year incidence of chronic GVHD was 0.07 (95% CI, 0.03-0.13) vs 0.05 (95% CI, 0.02-0.11), respectively (P = .518). In conclusion, both chemotherapeutic conditioning regimens were well tolerated and NRM was low. However, relapse was the major cause of treatment failure. This trial was registered at www.clinicaltrials.gov as #NCT01949129.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bader P, Pötschger U, Dalle JH, et al. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. Blood Adv. 2024. PMID: 37738088. doi:10.1182/bloodadvances.2023010591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。